Scynexis resumes dosing in Phase III MARIO study after lengthy delay
Scynexis has resumed dosing of its Brexafemme (ibrexafungerp) drug in a Phase III trial after a 19-month clinical hold by the FDA.
Scynexis has resumed dosing of its Brexafemme (ibrexafungerp) drug in a Phase III trial after a 19-month clinical hold by the FDA.
What's Your Reaction?
